Abstract
The advent of the biological era has seen many improvements in the management of inflammatory bowel disease (IBD). These agents, however, are not a ubiquitous panacea as they are neither universally available nor are they universally efficacious in the short or long-term. There is, therefore, still a need for other therapies and it is important to remember about the medications that have been effective in the past. The use of azathioprine and 6-mercoptopurine has been the mainstay of long-term therapy for many IBD patients for many years. Their role as steroid sparing agents and in the maintenance of remission is well recognized, and with the advent of metabolite testing their use has been refined. Methotrexate is a second line immunomodulator with less impressive data but still with observed benefits in Crohns disease (CD) and two newer immunosuppressive agents, mycophenylate mofetil and tacrolimus have sparked some interest as they appear to be efficacious in some patients.
As IBD is a chronic incurable condition that primarily presents in young patients, the treating clinicians goal is to induce and maintain long-term remission. So when one agent is ineffective, or unavailable, other agents need to be considered. This review aims to provide clinicians with practical and up to date knowledge about the use of the immunomodulators in the management of IBD, which is vital in order to offer the best management for their patients.
Keywords: Azathioprine, immunosuppression, inflammatory bowel disease, methotrexate, mycophenoylate mofetil, tacrolimus, 6-mercaptopurine, TPMT, Mycophenolate mofetil
Current Drug Targets
Title: Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD
Volume: 12 Issue: 9
Author(s): O. R. Waters and I. C. Lawrance
Affiliation:
Keywords: Azathioprine, immunosuppression, inflammatory bowel disease, methotrexate, mycophenoylate mofetil, tacrolimus, 6-mercaptopurine, TPMT, Mycophenolate mofetil
Abstract: The advent of the biological era has seen many improvements in the management of inflammatory bowel disease (IBD). These agents, however, are not a ubiquitous panacea as they are neither universally available nor are they universally efficacious in the short or long-term. There is, therefore, still a need for other therapies and it is important to remember about the medications that have been effective in the past. The use of azathioprine and 6-mercoptopurine has been the mainstay of long-term therapy for many IBD patients for many years. Their role as steroid sparing agents and in the maintenance of remission is well recognized, and with the advent of metabolite testing their use has been refined. Methotrexate is a second line immunomodulator with less impressive data but still with observed benefits in Crohns disease (CD) and two newer immunosuppressive agents, mycophenylate mofetil and tacrolimus have sparked some interest as they appear to be efficacious in some patients.
As IBD is a chronic incurable condition that primarily presents in young patients, the treating clinicians goal is to induce and maintain long-term remission. So when one agent is ineffective, or unavailable, other agents need to be considered. This review aims to provide clinicians with practical and up to date knowledge about the use of the immunomodulators in the management of IBD, which is vital in order to offer the best management for their patients.
Export Options
About this article
Cite this article as:
R. Waters O. and C. Lawrance I., Understanding the Use of Immunosuppressive Agents in the Clinical Management of IBD, Current Drug Targets 2011; 12 (9) . https://dx.doi.org/10.2174/138945011796150343
DOI https://dx.doi.org/10.2174/138945011796150343 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
High Sensitivity Troponin in Cardiovascular Disease. Is There More Than a Marker of Myocardial Death?
Current Topics in Medicinal Chemistry Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry Blood Pressure Control and Diabetic Retinopathy
Current Hypertension Reviews Perioperative Considerations in Patients with Obstructive Sleep Apnea
Current Respiratory Medicine Reviews A Pilot Study to Assess Adenosine 5’-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection
Cardiovascular & Hematological Disorders-Drug Targets PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Preface [Hot Topic: Chromogranin A and Its Derived Peptides as Potential Regulators of Immune, Endocrine and Metabolic Systems - In Search of Its Physiological Role (Guest Editors: K.B. Helle and G. Serck-Hanssen)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cabazitaxel: A Novel Drug for Hormone-Refractory Prostate Cancer
Mini-Reviews in Medicinal Chemistry Isolation and Purification of Kudinosides from Kuding Tea by Semi-Preparative HPLC Combined with MCI-GEL Resin
Current Analytical Chemistry Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Current Drug Targets Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Role of Vascular Nitric Oxide in Experimental Liver Cirrhosis
Current Vascular Pharmacology Food-derived Bioactive Peptides - Opportunities for Designing Future Foods
Current Pharmaceutical Design Aporphines and Parkinson’s Disease: Medical Tools for the Future
Current Topics in Medicinal Chemistry The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review
Current Neuropharmacology Crystallization and Preliminary Crystallographic Studies of an Antitumour Lectin from the Edible Mushroom Agrocybe aegerita
Protein & Peptide Letters Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection
Current Drug Targets Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design The Role of Corticosteroids in Sepsis and Acute Respiratory Distress Syndrome
Current Respiratory Medicine Reviews